ATP13A2: Potential Drug Target and Biomarker (G23400)

Target Name: ATP13A2

NCBI ID: G23400

ATP13A2

ATP13A2: Potential Drug Target and Biomarker

ATP13A2 (ATP13A2 variant 2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and skeletal muscles. It is a key regulator of muscle growth and repair, and is involved in the development and maintenance of muscle mass. In addition, ATP13A2 is also known to play a role in the regulation of cellular signaling pathways, which are important for a wide range of cellular processes.

The research on ATP13A2 has been ongoing for several years, and there is a growing interest in using it as a drug target or biomarker. This is because of its potential role in the treatment of various diseases, including cancer, neurodegenerative diseases, and muscle- related conditions.

Diseases and Conditions associated with ATP13A2

One of the primary targets of studies of ATP13A2 is its role in cancer. High levels of ATP13A2 have been observed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, studies have shown that inhibiting ATP13A2 can lead to the growth and progression of cancer cells.

In addition to its potential role in cancer, ATP13A2 is also being studied for its potential role in neurodegenerative diseases. Alzheimer's disease, Parkinson's disease, and Huntington's disease are all characterized by the progressive loss of brain cells, and it is thought that the underlying cause of these diseases may be the regulation of ATP13A2.

ATP13A2 is also being studied for its potential role in muscle-related conditions, such as myopathies, which are characterized by muscle weakness or dysfunction. Studies have shown that ATP13A2 plays a role in the regulation of muscle growth and repair, and that inhibiting its activity can lead to muscle weakness or dysfunction.

The Potential Therapeutic Benefits of ATP13A2

The therapeutic potential benefits of ATP13A2 are vast and varied. If its anti-cancer properties are exploited, it could be used to treat various types of cancer. Additionally, by inhibiting the regulation of ATP13A2, it could be used to treat neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.

In addition to its potential therapeutic benefits, ATP13A2 is also being studied as a potential biomarker. Its expression has been observed in a wide range of tissues, including cancer cells, neurodegenerative cells, and muscle cells. This makes it a potential candidate for use as a biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and muscle-related conditions.

The Identification of ATP13A2 as a Drug Target

The identification of ATP13A2 as a drug target is based on several factors. First, its expression has been observed in a wide range of tissues, including cancer cells, neurodegenerative cells, and muscle cells, which suggests that it may be involved in the regulation of cellular processes that are important for the growth, repair, and survival of these cells.

In addition, studies have shown that inhibiting the regulation of ATP13A2 can lead to the growth and progression of cancer cells. This suggests that ATP13A2 may be involved in the regulation of the growth and progression of cancer cells, which could make it an attractive target for cancer therapies.

Furthermore, the regulation of ATP13A2 has been implicated in the regulation of cellular signaling pathways that are important for a wide range

Protein Name: ATPase Cation Transporting 13A2

Functions: ATPase which acts as a lysosomal polyamine exporter with high affinity for spermine (PubMed:31996848). Also stimulates cellular uptake of polyamines and protects against polyamine toxicity (PubMed:31996848). Plays a role in intracellular cation homeostasis and the maintenance of neuronal integrity (PubMed:22186024). Contributes to cellular zinc homeostasis (PubMed:24603074). Confers cellular protection against Mn(2+) and Zn(2+) toxicity and mitochondrial stress (PubMed:26134396). Required for proper lysosomal and mitochondrial maintenance (PubMed:22296644, PubMed:28137957). Regulates the autophagy-lysosome pathway through the control of SYT11 expression at both transcriptional and post-translational levels (PubMed:27278822). Facilitates recruitment of deacetylase HDAC6 to lysosomes to deacetylate CTTN, leading to actin polymerization, promotion of autophagosome-lysosome fusion and completion of autophagy (PubMed:30538141). Promotes secretion of exosomes as well as secretion of SCNA via exosomes (PubMed:25392495, PubMed:24603074). Plays a role in lipid homeostasis (PubMed:31132336)

The "ATP13A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP13A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets